drugset / Trial / NCT06289894
A Study of BRY805 in Participants With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors.
Timeline
- Start
- 2024-03-13
- Primary completion
- 2025-05-16
- Completion
- 2025-07-04
Outcome
Outcome not reported
Stopped (Business): “Adjustment of the company's R\&D strategy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRY805 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | BRY805 | Unknown | 1 mg/kg | Intravenous |
| Subject | BRY805 | Unknown | 3 mg/kg | Intravenous |
| Subject | BRY805 | Unknown | 9 mg/kg | Intravenous |
| Subject | BRY805 | Unknown | 18 mg/kg | Intravenous |
| Subject | BRY805 | Unknown | 30 mg/kg | Intravenous |